Rockwell Medical Q2 2026 Earnings Report

Rockwell Medical EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.24
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Rockwell Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $17.82 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rockwell Medical Announcement Details

• Quarter: Q2 2026
• Date: 8/13/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 13, 2026
• Conference Call Time: 8:00AM ET

Rockwell Medical (NASDAQ:RMTI) is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients. TRIFERIC is delivered via dialysate and is intended to replace iron losses that occur during the dialysis process, helping to maintain hemoglobin levels without the need for intravenous iron supplements. In addition to TRIFERIC, Rockwell Medical offers a generic injectable formulation of calcitriol, a form of vitamin D used to manage secondary hyperparathyroidism in CKD patients.

Since its founding in 1991, Rockwell Medical has conducted research, clinical development, and regulatory activities primarily in the United States. The company collaborates with specialty distributors and dialysis providers to commercialize its products and is exploring further innovations, including oral formulations of its iron therapy. Rockwell Medical’s operations are led by an experienced management team with backgrounds in nephrology, pharmaceutical development, and health-care commercialization, reflecting its commitment to improving patient outcomes in the CKD community.